High Cholesterol Management
All adults with high cholesterol should start with maximally tolerated statin therapy as first-line treatment, with specific LDL-C goals and add-on therapies determined by their absolute ASCVD risk category. 1
Risk-Stratified Treatment Approach
The 2026 ACC/AHA guidelines provide a clear algorithmic framework based on LDL-C levels and ASCVD risk:
Severe Hypercholesterolemia (LDL-C ≥190 mg/dL)
First, exclude and address secondary causes of dyslipidemia (hypothyroidism, nephrotic syndrome, medications) before initiating treatment. 1
Initial therapy: Start maximally tolerated statin immediately. 1
Then stratify by risk:
Without Clinical ASCVD, HeFH, or Additional Risk Factors
- Add ezetimibe, PCSK9 mAb, and/or bempedoic acid to achieve:
- LDL-C <100 mg/dL
- Non-HDL-C <130 mg/dL 1
With HeFH, Additional Risk Factors, or Coronary Calcification
- Add ezetimibe, PCSK9 mAb, and/or bempedoic acid to achieve more aggressive targets:
- LDL-C <70 mg/dL
- Non-HDL-C <100 mg/dL 1
With Clinical ASCVD (MI, stroke, revascularization, PAD)
- Add ezetimibe, PCSK9 mAb, and/or bempedoic acid to achieve the most aggressive targets:
- LDL-C <55 mg/dL
- Non-HDL-C <85 mg/dL 1
Important caveat: These are Class 1 (strongest) recommendations with Level B evidence, representing a major shift from 2018 guidelines where PCSK9 inhibitors were only Class 2b (may be considered) for heterozygous FH. 1
Moderate Hypercholesterolemia (LDL-C 70-189 mg/dL)
Calculate 10-year ASCVD risk using the PREVENT equations (not the older Pooled Cohort Equations). 1
For high-risk patients (≥10% 10-year risk):
- Start maximally tolerated statin
- If LDL-C remains ≥70 mg/dL and non-HDL-C ≥100 mg/dL, add ezetimibe 1
Diabetes Without Clinical ASCVD (Ages 40-75)
Start moderate-intensity statin to achieve:
- ≥30-49% LDL-C reduction
- LDL-C <100 mg/dL
- Non-HDL-C <130 mg/dL 1
For those with multiple ASCVD risk factors, escalate to high-intensity statin 1
Medication Hierarchy
The evidence strongly supports this sequential approach:
- Statins first (high-intensity preferred: atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
- Add ezetimibe if goals not met (provides additional 15-20% LDL-C reduction)
- Add PCSK9 inhibitor (evolocumab, alirocumab) or bempedoic acid if still not at goal
- Inclisiran is reasonable as a second-line PCSK9 inhibitor when LDL-C ≥100 mg/dL despite statin ± ezetimibe, though cardiovascular outcomes trials are pending 1
Critical point: The guidelines now recommend combination therapy upfront for highest-risk patients rather than sequential titration, representing a paradigm shift toward more aggressive early treatment. 1
Special Populations
Familial Hypercholesterolemia
Heterozygous FH:
- Genetic testing is reasonable to identify higher-risk individuals 1
- Do not use standard risk calculators (Class 3 recommendation) 1
- Treatment goals: LDL-C <70 mg/dL if no clinical ASCVD 2
Homozygous FH:
- Start treatment by age 2 years
- Use all available medications (statin, ezetimibe, PCSK9 inhibitor)
- Consider lomitapide or evinacumab if LDL-C ≥100 mg/dL despite maximal therapy
- Lipoprotein apheresis by age 3-8 years if goals not met 2
Hypertriglyceridemia
For triglycerides >500 mg/dL:
- Primary intervention: aggressive lifestyle modification (diet, exercise, weight loss, alcohol abstinence)
- Pharmacotherapy: fibrates or statins 3
- Pitfall: Elevated total cholesterol from hypertriglyceridemia can be mistaken for LDL-C elevation—always check fasting lipid panel 4
Monitoring Strategy
- Measure lipids at baseline and 4-12 weeks after initiating or adjusting therapy
- Once at goal, monitor every 3-12 months
- Non-fasting samples acceptable for monitoring stable therapy 2
- Check liver enzymes, CK, glucose, and creatinine before starting statins 2
Common Pitfalls to Avoid
Undertreating high-risk patients: Only ~20% of high-risk patients achieve LDL-C <70 mg/dL in practice, often because clinicians use low-dose statins when high-dose or combination therapy is needed 5
Delaying combination therapy: Don't wait months to add ezetimibe or PCSK9 inhibitors in very high-risk patients—the guidelines now support earlier, more aggressive combination therapy 1
Using wrong risk calculator: The PREVENT equations should replace Pooled Cohort Equations, as they provide more accurate contemporary risk estimates 1, 6
Ignoring coronary artery calcium (CAC): CAC scoring improves risk stratification beyond traditional risk factors and should guide treatment intensity 6
The overarching principle: "Lower for longer is better"—earlier, more aggressive LDL-C lowering reduces lifetime ASCVD risk, with evidence supporting treatment to LDL-C as low as <30 mg/dL in very high-risk patients without significant adverse events. 6, 7